Advances in the Treatment of Mucoepidermoid Carcinoma

Mucoepidermoid carcinoma (MEC) represents 10-15% of salivary neoplasms. Due to their low incidence, it is challenging to conduct clinical trials and develop treatment guidelines. Although surgery is the most common approach for a resectable tumor, various treatment options such as chemotherapy, radiotherapy, and immunotherapy have been investigated. There is a need to implement a standardized treatment protocol to effectively manage MEC as it is a common histological subtype. Furthermore, it has become essential to assess chromosomal and genetic abnormalities recently identified with MEC, including alterations of CDKN2A, TP53, CDKN2B, BAP1, etc. These mutations are involved in the transformation of low-grade tumors to high-grade tumors, presenting a vital tool for evaluating the aggressive behavior of this carcinoma. Detailed immunohistochemical and translocation studies can help develop targeted therapies and monitor treatment response. Therefore, biomarker-driven research will immensely improve the outcome, especially in advanced cases. Based on thorough histology and chromosomal translocations, a more personalized treatment plan can improve the overall disease outcome. The purpose of this article is to elaborate on the current treatment advancements, particularly chemotherapy and targeted therapy, as an effective treatment modality for the management of MEC and highlight the comparison with traditional treatment approaches.

Automated summary

Mucoepidermoid carcinoma (MEC) is a common subtype of salivary neoplasms, but its low incidence poses challenges in clinical trials and treatment guideline development. Surgery is the most common approach for resectable tumors, but other options such as chemotherapy, radiotherapy, and immunotherapy are being investigated. Standardized treatment protocols and assessment of chromosomal and genetic abnormalities are necessary for effective management of MEC. Biomarker-driven research can greatly improve outcomes, especially in advanced cases.